All In Biotech

Drug Trial Radar · NCT06799286

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

An Open-label, Single-arm, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

May 7, 2025

Primary completion

Sep 9, 2026

Study completion Sep 9, 2026

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).

Conditions

  • Small Cell Lung Carcinoma

Interventions

  • BMS-986489Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Up to 19 months after last participant's first treatment
  2. Number of participants with Serious AEs (SAEs)Time frame: Up to 19 months after last participant's first treatment
  3. Number of participants with AEs leading to discontinuation of study treatmentTime frame: Up to 19 months after last participant's first treatment
  4. Number of participants with select AEsTime frame: Up to 19 months after last participant's first treatment
  5. Number of participants with immune-mediated AEs (IMAEs)Time frame: Up to 19 months after last participant's first treatment
  6. Number of deathsTime frame: Up to 19 months after last participant's first treatment
  7. Number of participants with laboratory abnormalitiesTime frame: Up to 19 months after last participant's first treatment
  8. Maximum observed concentration (Cmax) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
  9. Time of maximum observed concentration (Tmax) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
  10. Trough observed plasma concentration (Ctrough) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
  11. Concentration at the end of a dosing interval (Ctau) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
  12. Average concentration over a dosing interval ([AUC(TAU)/TAU]) (Cavg(TAU)) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
  13. Area under the concentration-time curve within one dosing interval (AUC(TAU)) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
  14. Total body clearance (CLT) for BMS-986012Time frame: Up to 19 months after last participant's first treatment
  15. Observed concentration at end of infusion (Ceoi) for BMS-986012Time frame: Up to 19 months after last participant's first treatment

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0002

    Shanghai, China

  • Local Institution - 0004

    Beijing, Beijing Municipality, China

  • Local Institution - 0003

    Jinan, Shandong, China

  • Local Institution - 0001

    Linyi, Shandong, China

  • Local Institution - 0005

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.